Literature DB >> 3916569

Chemotherapy of urologic malignancies.

H I Scher, C N Sternberg.   

Abstract

Entities:  

Mesh：

Year:  1985        PMID： 3916569

Source DB:  PubMed          Journal:  Semin Urol        ISSN： 0730-9147


× No keyword cloud information.
  5 in total

1.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth.

Authors:  Zhang Weihua; Richard Lathe; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Authors:  A Canada; L Herman; K Kidd; C Robertson; D Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Phase I/II trial of intravesical methotrexate for superficial bladder tumors.

Authors:  C N Sternberg; A Yagoda; N H Bander; W F Whitmore; J L Huffman; M Fleisher; M Melamed; M P Fanucchi; P Hollander; E D Vaughan
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

Authors:  H I Scher; C Sternberg; W D Heston; R C Watson; D Niedzwiecki; T Smart; P Hollander; A Yagoda
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  [Chemotherapy of hormone refractory prostate carcinoma].

Authors:  M P Wirth; J Nippgen
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.